{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T10:49:27Z","timestamp":1792234167199,"version":"4.4.0"},"reference-count":23,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T00:00:00Z","timestamp":1742774400000},"content-version":"vor","delay-in-days":23,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["HemaSphere"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Polycythemia vera (PV) is a myeloproliferative neoplasm associated with a high symptom and psychological burden, resulting in decreased quality of life (QoL). Patients with PV have an increased risk of cardiovascular (CV) complications, making regular monitoring crucial. The Landmark 2.0 survey was conducted worldwide among patients with PV and their treating physicians to identify any potential gaps in perceptions regarding PV management. Data were collected between April 2021 and April 2022 from physicians and patients across 11 countries. Overall, 133 physicians and 274 patients with PV participated in the survey. There were discrepancies between physicians and patients in reporting whether symptom assessments and basic CV assessments were conducted during routine visits (83% vs. 68% and 64% vs. 55%, respectively). Emotional assessments were not performed routinely (reported by 36% of physicians and 34% of patients). Patients attributed the highest impact on QoL to physical symptoms (67%); however, physicians were less likely to report highly prevalent symptoms such as bruising, difficulty sleeping, inactivity, and depression among the most common symptoms. While both physicians and patients aimed for symptom improvement, their treatment goals differed: physicians focused on managing hematocrit, preventing thrombotic events, and reducing spleen size, while patients focused on slowing down disease progression. Patient satisfaction with treatment was generally high but decreased in later therapy stages. Overall, these data underscore the disparity in patient\u2013physician perceptions of PV management and treatment expectations, showing the gaps in communication and the need for greater patient education, as well as highlighting areas for potential improvement in clinical practice.<\/jats:p>","DOI":"10.1002\/hem3.70106","type":"journal-article","created":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T10:05:12Z","timestamp":1742897112000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Patient and physician perceptions regarding treatment expectations and symptomatology in polycythemia vera: Insights from the Landmark 2.0 global health survey"],"prefix":"10.1002","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3212-920X","authenticated-orcid":false,"given":"Claire N.","family":"Harrison","sequence":"first","affiliation":[{"name":"Guy's and St Thomas' NHS Foundation Trust London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Ross","sequence":"additional","affiliation":[{"name":"Royal Adelaide Hospital and SA Pathology Adelaide Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura Maria","family":"Fogliatto","sequence":"additional","affiliation":[{"name":"Hospital de Clinicas de Porto Alegre Porto Alegre Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynda","family":"Foltz","sequence":"additional","affiliation":[{"name":"University of British Columbia Vancouver British Columbia Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lambert","family":"Busque","sequence":"additional","affiliation":[{"name":"H\u00f4pital Maisonneuve\u2010Rosemont, University of Montreal Montreal Quebec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijian","family":"Xiao","sequence":"additional","affiliation":[{"name":"Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences &amp; Peking Union Medical College Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian H.","family":"Heidel","sequence":"additional","affiliation":[{"name":"Hematology, Hemostasis, Oncology and Stem Cell Transplantation Hannover Medical School (MHH) Hannover Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Koehler","sequence":"additional","affiliation":[{"name":"Specialty Practice for Psycho\u2010Oncology Magdeburg Germany"},{"name":"Department of Hematology, Oncology, and Cell Therapy, Medical Center Otto\u2010von\u2010Guericke University Magdeburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe A.","family":"Palumbo","sequence":"additional","affiliation":[{"name":"Dipartimento di Scienze Mediche Chirurgiche e Tecnologie Avanzate \u201cG.F. Ingrassia\u201d University of Catania Catania Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Breccia","sequence":"additional","affiliation":[{"name":"University of Rome La Sapienza Roma Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Komatsu","sequence":"additional","affiliation":[{"name":"Juntendo University School of Medicine Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keita","family":"Kirito","sequence":"additional","affiliation":[{"name":"University of Yamanashi Chuo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blanca","family":"Xicoy Cirici","sequence":"additional","affiliation":[{"name":"ICO Hospital Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Universitat Aut\u00f2noma de Barcelona Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquin","family":"Martinez\u2010Lopez","sequence":"additional","affiliation":[{"name":"University Hospital October 12, I+12 institute, CNI, CIBERONC, Complutense University Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Rovo","sequence":"additional","affiliation":[{"name":"Department of Hematology and Central Hematology Laboratory Inselspital, University Hospital of Bern Bern Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl","family":"Petruk","sequence":"additional","affiliation":[{"name":"Heal Canada Markham Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catalin","family":"Bobirca","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Mirams","sequence":"additional","affiliation":[{"name":"Adelphi Real World Bollington United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail","family":"McMillan","sequence":"additional","affiliation":[{"name":"Adelphi Real World Bollington United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin","family":"Harper","sequence":"additional","affiliation":[{"name":"Adelphi Real World Bollington United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean\u2010Jacques","family":"Kiladjian","sequence":"additional","affiliation":[{"name":"AP\u2010HP H\u00f4pital Saint\u2010Louis, Universit\u00e9 Paris Cit\u00e9, INSERM CIC1427 Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,3,24]]},"reference":[{"issue":"2","key":"e_1_2_10_2_1","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1182\/blood-2011-01-328955","article-title":"The Myeloproliferative Neoplasm Symptom Assessment Form (MPN\u2010SAF): international prospective validation and reliability trial in 402 patients","volume":"118","author":"Scherber R","year":"2011","journal-title":"Blood"},{"issue":"16","key":"e_1_2_10_3_1","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21165805","article-title":"New perspectives on polycythemia vera: from diagnosis to therapy","volume":"21","author":"Iurlo A","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"11","key":"e_1_2_10_4_1","first-page":"680","article-title":"Polycythemia vera: rapid evidence review","volume":"103","author":"Fox S","year":"2021","journal-title":"Am Fam Physician"},{"issue":"9","key":"e_1_2_10_5_1","doi-asserted-by":"crossref","first-page":"656","DOI":"10.7326\/0003-4819-123-9-199511010-00003","article-title":"Polycythemia vera: the natural history of 1213 patients followed for 20 years","volume":"123","author":"Gruppo Italiano Studio Policitemia","year":"1995","journal-title":"Ann Intern Med"},{"issue":"10","key":"e_1_2_10_6_1","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1200\/JCO.2005.07.062","article-title":"Vascular and neoplastic risk in a large cohort of patients with polycythemia vera","volume":"23","author":"Marchioli R","year":"2005","journal-title":"J Clin Oncol"},{"issue":"4","key":"e_1_2_10_7_1","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1055\/s-2007-976165","article-title":"Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F","volume":"33","author":"Tefferi A","year":"2007","journal-title":"Semin Thromb Hemost"},{"issue":"4","key":"e_1_2_10_8_1","doi-asserted-by":"crossref","first-page":"E107","DOI":"10.1002\/ajh.25407","article-title":"Changing incidence of myeloproliferative neoplasms in Australia, 2003\u20102014","volume":"94","author":"Baade PD","year":"2019","journal-title":"Am J Hematol"},{"key":"e_1_2_10_9_1","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s12885-016-2208-2","article-title":"Myeloproliferative neoplasms (MPNs) have a significant impact on patients' overall health and productivity: the MPN Landmark survey","volume":"16","author":"Mesa R","year":"2016","journal-title":"BMC Cancer"},{"issue":"3","key":"e_1_2_10_10_1","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/cncr.30325","article-title":"Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists\/oncologists in the United States: Findings from the MPN Landmark survey","volume":"123","author":"Mesa RA","year":"2017","journal-title":"Cancer"},{"issue":"10","key":"e_1_2_10_11_1","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1007\/s00277-017-3082-y","article-title":"The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey","volume":"96","author":"Harrison CN","year":"2017","journal-title":"Ann Hematol"},{"issue":"1","key":"e_1_2_10_12_1","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1186\/s12885-018-4322-9","article-title":"Impact of myeloproliferative neoplasms on patients' employment status and work productivity in the United States: results from the living with MPNs survey","volume":"18","author":"Yu J","year":"2018","journal-title":"BMC Cancer"},{"issue":"5","key":"e_1_2_10_13_1","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s00277-019-03610-4","article-title":"Relationship between symptom burden and disability leave among patients with myeloproliferative neoplasms (MPNs): findings from the Living with MPN patient survey","volume":"98","author":"Yu J","year":"2019","journal-title":"Ann Hematol"},{"key":"e_1_2_10_14_1","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1186\/s12889-015-2034-5","article-title":"Self\u2010reported symptoms and healthcare seeking in the general population\u2010\u2010exploring \u201cThe Symptom Iceberg\u201d","volume":"15","author":"Elnegaard S","year":"2015","journal-title":"BMC Public Health"},{"issue":"6","key":"e_1_2_10_15_1","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/fampra\/cmy023","article-title":"Non\u2010disclosure of symptoms in primary care: an observational study","volume":"35","author":"Paskins Z","year":"2018","journal-title":"Fam Pract"},{"issue":"4","key":"e_1_2_10_16_1","doi-asserted-by":"crossref","first-page":"788","DOI":"10.3324\/haematol.2013.093724","article-title":"Patient\u2010 versus physician\u2010reporting of symptoms and health status in chronic myeloid leukemia","volume":"99","author":"Efficace F","year":"2014","journal-title":"Haematologica"},{"issue":"6","key":"e_1_2_10_17_1","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1007\/s10903-008-9135-5","article-title":"The role of culture in health literacy and chronic disease screening and management","volume":"11","author":"Shaw SJ","year":"2009","journal-title":"J Immigr Minor Health"},{"key":"e_1_2_10_18_1","doi-asserted-by":"crossref","first-page":"e89","DOI":"10.1200\/EDBK_158749","article-title":"Electronic patient\u2010reported outcomes: the time is ripe for integration into patient care and clinical research","volume":"35","author":"Schwartzberg L","year":"2016","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"6","key":"e_1_2_10_19_1","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1007\/s00277-024-05704-0","article-title":"Ruxolitinib adherence in myelofibrosis and polycythemia vera: the \u201cRAMP\u201d Italian multicenter prospective study","volume":"103","author":"Palandri F","year":"2024","journal-title":"Ann Hematol"},{"issue":"3","key":"e_1_2_10_20_1","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/ejh.12588","article-title":"Risk factors for non\u2010melanoma skin cancer in patients with essential thrombocythemia and polycythemia vera","volume":"96","author":"G\u00f3mez M","year":"2016","journal-title":"Eur J Haematol"},{"issue":"2","key":"e_1_2_10_21_1","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/s41375-020-0945-3","article-title":"Significant association of cutaneous adverse events with hydroxyurea: results from a prospective non\u2010interventional study in BCR\u2010ABL1\u2010negative myeloproliferative neoplasms (MPN) \u2010 on behalf of the German Study Group\u2010MPN","volume":"35","author":"Stegelmann F","year":"2021","journal-title":"Leukemia"},{"issue":"2","key":"e_1_2_10_22_1","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1182\/blood.2023022345","article-title":"Outcomes and characteristics of nonmelanoma skin cancers in patients with myeloproliferative neoplasms on ruxolitinib","volume":"143","author":"Rampotas A","year":"2024","journal-title":"Blood"},{"issue":"1","key":"e_1_2_10_23_1","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.5045\/br.2021.2020325","article-title":"Disease modifying agents of myeloproliferative neoplasms: a review","volume":"56","author":"Lee SE","year":"2021","journal-title":"Blood Res"},{"issue":"22","key":"e_1_2_10_24_1","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1182\/blood.2023021503","article-title":"Moving toward disease modification in polycythemia vera","volume":"142","author":"Bewersdorf JP","year":"2023","journal-title":"Blood"}],"container-title":["HemaSphere"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hem3.70106","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T23:34:03Z","timestamp":1743377643000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hem3.70106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.1002\/hem3.70106"],"URL":"https:\/\/doi.org\/10.1002\/hem3.70106","archive":["Portico"],"relation":{},"ISSN":["2572-9241","2572-9241"],"issn-type":[{"value":"2572-9241","type":"print"},{"value":"2572-9241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"2024-09-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70106"}}